HoV. Acne management for the 90s: Current treatment guidelines. Can J Diagnosis1995; (Suppl):5–25.
2.
LivnehH. On the origins of negative attitudes toward people with disabilities. Rehab Lit1982; 43:338–347.
3.
Van der MeerenHLMvan der SchaarWWvan den HurkMAM. The psychological impact of severe acne. Cutis1985; 36:84–86.
4.
SchusterSFisherGHHarrisE. The effect of skin disease on self image. Br J Dermatol1978; 99(Suppl 16):18–19.
5.
KellettSCGawkrodgerDJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol1999; 140:273–282.
6.
GuptaMAGuptaAK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol1998; 139:846–850.
7.
LaytonAM. Acne scarring—reviewing the need for the early treatment of acne. J Dermatol Treat2000; 11:3–6.
8.
JowettSRyanT. Skin disease and handicap. An analysis of the impact of skin conditions. Soc Sci Med1985; 20:425–429.
9.
CunliffeWJ. Acne and unemployment. Br J Dermatol1986; 115:386.
10.
SulzbergerMBZaidensSH. Psychogenic factors in dermatologic disorder. Med Clin North Am1948; 32:669–672.
11.
LaytonAHendersonCACunliffeWJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol1994; 19:303–308.
CunliffeWJSimpsonNB. Disorders of the subaceous glands. In: ChampionRWilkinsonDSEblingFJC, eds. Textbook of dermatology. 6th Ed.Maiden, PA: Blackwell Science, 1998:1964–1970.
14.
LeydenJJ. Therapy for acne vulgaris. N Engl J Med1997; 336:1156–1162.
15.
HarmsMMasouyéIRadeffB. The relapses of cystic acne after isotretinoin treatment are age related: A long-term follow-up study. Dermatologica1986; 172:148–153.
16.
LaytonAMStainforthJMCunliffeWJ. Ten years' experience of oral isotretinoin for the treatment of acne vulgaris. J Dermatol Treat1993; 4(Suppl 2):S2–S5.
17.
WhiteGM. Recurrence rates after the first course of isotretinoin. Arch Dermatol1998; 134:376–378.
18.
KingKJonesDHDaltreyDCCunliffeWJ. A double-blind study of the effects of 13-cis retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol1982; 107:583–590.
19.
DalzielKBartonSMarksR. The effects of isotretinoin on follicular and sebaceous gland differentiation. Br J Dermatol1987; 117:317–323.
20.
LeydenJJMcGinleyKJ. Effect of 13-cis retinoic acid on sebum production and Propionibacterium acnes in severe nodulocystic acne. Arch Dermatol Res1982; 272:331–337.
21.
FalconRHLeeWLShalitaAR. In vitro effect of isotretinoin on monocyte Chemotaxis. J Invest Dermatol1986; 86:550–552.
22.
CunliffeWJvan de KerkhofPCMCaputoR. Accutane treatment guidelines: Results of an international survey. Dermatology1997; 194:351–357.
MaddinS. Current dermatologic therapy II. 2nd Ed.Philadelphia: WB Saunders, 1991.
26.
ClarkSMCunliffeWJ. Acne flare and isotretinoin—incidence and treatment. Br J Dermatol1995; 113(Suppl 45):26.
27.
WilloughbyJSRosenthalD. Monitoring isotretinoin therapy in acne: Rational use of laboratory tests. J Cutan Med Surg1997; 2:72–77.
28.
BarthJHMacdonald-HullSPMarkJ. Isotretinoin therapy for acne vulgaris: A re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol1993; 129:704–707.
29.
MarsdenJR. Lipid metabolis and retinoid therapy. Pharmacol Ther1989; 40:55–65.
30.
RagosGRHouldenRLDanbyFW. Effect of isotretinoin therapy on serum total cholesterol and triglycerides. Can J Clin Pharmacol1998; 5:43–47.
31.
SearlesGEOoiTC. Underrecognition of chylomicronemia as a cause of acute pancreatitis. Can Med Assoc J1992; 147:1806–1808.
32.
ZimmermanHJ. Drug and toxin-induced liver disease. In: SteinJH, ed. Internal medicine. 5th Ed.St. Louis, MO: Mosby, 1998.
33.
SimpsonNB. Social and economic aspects of acne and the cost-effectiveness of isotretinoin. J Dermatol Treat1993; 4(Suppl 2):S6–S9.
34.
WesselsFAndersonANKropmanK. The cost-effectiveness of isotretinoin in the treatment of acne. S Afr Med J1999; 89:780–794.
35.
SolishNRamenMPollackSV. Approaches to acne scarring: A review. J Cutan Med Surg1998; 2(Suppl 3):24–32.
36.
CunliffeWJ. Chapter 19; Treatment of acne scars. In: Acne, 1989; 337–353. London, England: Martin Dunitz Ltd.
37.
GreenwoodRJonesDHBrommittL. Comparison of isotretinoin and cyproterone acetate—a clinical and laboratory study. In: CunliffeWJMillerAJ, eds. Retinoid therapyLancaster, UK: MTP Press, 1984:287–292.
38.
CunliffeWJ. The management of acne. Schering Dermatology.
39.
PattersonLPeedenJSirlinS. Morbidity and mortality weekly report: Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin. JAMA2000; 283:471.
40.
CoatesPAdamsCACunliffeWJ. Does oral isotretinion prevent P. acnes resistance?Dermatology1997; 195(Suppl l):4–9.
41.
JurzykRSSpielvogelRLRoseLI. Antiandrogens in the treatment of acne and hirsutism. Am Fam Phys1992; 45:1803–1806.
42.
BeswickSJDirekzeNGrovesRW. The pros and cons of Dianette treatment. Retinoids1997; 13:82–84.
43.
GreenwoodRBrummittLBurkeBCunliffeWJ. Acne: Double-blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. BMJ1985; 291:1231–1235.
44.
MonkBEAlmeydaJACaldwellIW. Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clin Exp Dermatol1987; 12:319–322.
45.
HanstedBReymannF. Cyproterone acetate in the treatment of acne vulgaris in adult females. Dermatologica1982; 164:117–126.
46.
ErkkolaRHirvonenELuikkuJ. Ovulation inhibitors containing cytproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand1990; 69:61–65.
CarlborgL. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Scand1986; (Suppl)134:29–32.
49.
AydinlikS. From Diane to Diane-35. In: BreckwaldtM, ed. Diagnosis and therapy of androgenization, 1992; 75–76. Berlin, Germany: Diesbag Verlag.
50.
AydinlikSLachnit-FixsonULehnertJ. Oestrogen-reduced ovulation inhibitors for the treatment of acne. A double-blind comparative study of Diane-35 and Diane. Fortschr Med1986; 104:3–10.
51.
ColverGBMortimerPSDawberRPR. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol1988; 118:95–99.
52.
ShawWSusumuYAyakoTItsuroH. Three cases of hepatocellular carcinoma among cyproterone users. Lancet1994; 344:1567–1568.
53.
HeinemannLAJWill-ShahabLKesterenPV. Safety of cyproterone acetate: Report of active surveillance. Pharmacoepidemiol Drug Saf1997; 6:169–178.
